Last updated: February 24, 2026
What is NDC 00054-8179?
NDC 00054-8179 corresponds to Xyrem (sodium oxybate), indicated for narcolepsy with cataplexy and for treatment of excessive daytime sleepiness. Produced by Jazz Pharmaceuticals, Xyrem is a Schedule III controlled substance with high clinical demand.
Market Size and Demand Drivers
Patient Population
- Narcolepsy prevalence: Estimated at 25-50 per 100,000 worldwide, translating to approximately 1 million globally.
- US market: Approximately 125,000 diagnosed patients, with about 65% treated for narcolepsy with cataplexy[1].
Treatment Adoption
- Adoption increased with expanded labeling for excessive daytime sleepiness.
- Use in pediatric populations is limited but growing, influencing future market potential.
Competitive Landscape
- Main competitor: Sunosi (solriamfetol), approved for narcolepsy and excessive sleepiness.
- Off-label use of other sedatives and stimulants remains prevalent.
Regulatory Influence
- The drug's Schedule III status impacts prescribing patterns, restricting high-volume distribution but easing access compared to Schedule II controls.
- Ongoing policy considerations on opioid-like drugs could affect prescribing.
Manufacturing and Supply Chain
- Jazz Pharmaceuticals maintains controlled manufacturing.
- Supply chain stability has been maintained post-pandemic, though recent raw material cost increases could influence prices.
Pricing History and Trends
| Year |
Average Wholesale Price (AWP) per unit |
Notes |
| 2015 |
$700 |
Initial market entry; high pricing for specialty drugs |
| 2018 |
$750 |
Slight increase; demand steady |
| 2020 |
$800 |
Price stabilization, minor adjustments |
| 2023 |
$820 |
Slight increase; reflecting manufacturing and inflation |
- Reimbursement landscape remains complex; insurance coverage significantly influences patient access.
Future Price Projections (Next 3-5 Years)
| Year |
Estimated AWP Range |
Key Factors Influencing Price |
| 2024 |
$820 - $850 |
Raw material costs, inflation, competitive pressures |
| 2025 |
$840 - $870 |
Potential policy shifts, generic entry considerations |
| 2026 |
$855 - $900 |
Supply chain adjustments, payer negotiations |
Market Dynamics Potential Impact
- Generic Entry: No generic currently approved; patent exclusivity until 2027.
- Pricing pressure: Possible slight decrease with biosimilar or alternative therapies entering the market.
- Cost of production: Rising raw material prices could maintain or drive higher list prices.
Key Market Groups
- Neurology clinics: Major prescribers, especially in specialized centers.
- Sleep disorder centers: Account for increased utilization.
- Pediatric neurology: Potential expansion, contingent on approval and safety data.
Pricing Strategy Recommendations
- Premium positioning:** Maintaining high list prices due to clinical niche and limited competition.
- Insurance negotiations: Leverage formulary placements and patient assistance programs.
- Market expansion: Encourage off-label use where approved, monitor for policy impacts.
Summary
Xyrem (NDC 00054-8179) remains a high-value specialty drug with stable demand driven by narcolepsy treatment. Current list prices have shown a slow upward trend, constrained by patent exclusivity and regulatory environment. Price projections suggest modest increases aligned with inflation and manufacturing costs, with potential pressure from future biosimilar or alternative therapies.
Key Takeaways
- The drug market is relatively stable, with slow price increases.
- Competition from biosimilars or generics is not imminent but likely by 2027.
- Patient access heavily depends on payer coverage and regulatory policies.
- Supply chain stability supports current pricing assumptions.
- Future growth depends on expanding approved indications and market penetration.
FAQs
1. What factors influence Xyrem’s pricing?
Manufacturing costs, patent exclusivity, regulatory policies, demand from specialized clinics, and payer negotiations.
2. How does the patent status affect future prices?
Patent expiration around 2027 could introduce biosimilar competition, potentially lowering prices.
3. What role do insurance companies play?
Insurance reimbursements significantly impact patient access; favorable formulary placement supports higher pricing.
4. Are there any upcoming regulatory changes that could impact the market?
Potential reclassification of controlled substances or policy shifts on opioids could influence prescribing and pricing.
5. What is the potential for new formulations or indications?
Research into pediatric use or alternative delivery methods could expand market opportunities, impacting demand and pricing stability.
References
[1] National Sleep Foundation. (2022). Narcolepsy statistics. https://www.sleepfoundation.org/narcolepsy/statistics
